TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data Private Market Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / ArsenalBio Stock

ArsenalBio Stock

arsenalbio.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $339.82MM

ArsenalBio is a biotechnology company looking to develop efficacious and safe cellular therapies for patients with chronic diseases and develops cellular drug discovery tools designed to provide medicines for cancer treatment. The company's tools operate in cell genome engineering and cell manufacturing platforms, enabling hospitals to create T-cell medicines for cancer treatment.

Buy or sell ArsenalBio stockLearn more about ArsenalBio IPO

Register To Buy and Sell Shares

For more details on financing and valuation for ArsenalBio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access ArsenalBio’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like ArsenalBio.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

ArsenalBio investors also invested in these private companies

Kleiner Perkins
Euclidean Capital
Westlake Village BioPartners
the Parker Institute

Team

Management Team

Tarjei Mikkelsen
Chief Technology Officer
Kenneth Drazan MD
Co-Founder, Director, Chief Executive Officer, President and Board Member
Jane Grogan
Chief Scientific Officer

Board Members

Sean Parker
Parker Institute for Cancer Immunotherapy
Alexander Marson Ph.D
Brook Byers Ph.D
Kleiner Perkins
Beth Seidenberg MD
Westlake Village BioPartners

Frequently Asked Questions About ArsenalBio’s Stock

plusminus
Can you buy ArsenalBio stock?
ArsenalBio is not publicly traded on NYSE or NASDAQ in the U.S. To buy ArsenalBio stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell ArsenalBio stock?
Yes, you can sell stock of a private company like ArsenalBio. Forge can help you sell your ArsenalBio stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is ArsenalBio’s stock price?
ArsenalBio is a privately held company and therefore does not have a public stock price. However, you may access ArsenalBio’s private market stock price with Forge Data.
plusminus
What is ArsenalBio’s stock ticker symbol?
ArsenalBio does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like ArsenalBio in the BioTech & Pharma sector

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$3.67B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

Atomwise

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$405.17MM

Mammoth Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.08B

Biosplice Therapeutics

Sector
Healthcare / BioTech & Pharma
 
 

Ginkgo Bioworks

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$4.89B

Caris Life Sciences

Sector
Healthcare / BioTech & Pharma
 
 

News Highlights

Crunchbase 09/08/2022
ArsenalBio Raises $220M As Cell Therapy’s Popularity Grows
As innovations in cell therapy continue to grow, San Francisco-based ArsenalBio this week announced it raised a whopping $220 million in Series B funding, one of the largest rounds this year for a cell therapy venture.
TechCrunch 10/17/2019
ArsenalBio emerges from stealth with $85 million and a dream team to fight cancer – TechCrunch
The story behind ArsenalBio begins with Sean Parker’s Institute for Cancer Immunotherapy. Founded in 2016, the Institute has been instrumental in providing a space for the top researchers into cancer across different fields to collaborate and communicate on the latest breakthroughs in setting…
FinSMEs 10/17/2019
ArsenalBio Raises $85M in Series A Financing | FinSMEs
ArsenalBio, a South San Francisco, Calif.-based programmable cell therapy company, raised $85m in Series A financing round

Trending Companies

Frequently Asked Questions

Updated on: Dec 8, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.